SIGA Technologies Inc.

Novel anti-infectives for biological warfare defense and emerging disease threats.

SIGA designs and develops novel countermeasures to prevent and treat serious infectious diseases, with an emphasis on biological warfare defense. SIGA’s leading program is ST-246®, an oral therapeutic agent active against orthopoxviruses including smallpox. Additional programs target arenaviruses such as Lassa fever, filoviruses such as Ebola and Marburg, flaviviruses such as Dengue fever, and other category A diseases.

The company has developed a proprietary discovery platform that can be applied to many pathogens. With strong working relationships with the National Institutes of Health (NIH), the Department of Defense, and other federal agencies, SIGA believes it is competitive with all other biodefense drug development companies today.